AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28196207 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 800 mg twice daily (800 mg/d)
Number of subjects: 695
Study 28196207 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 695
Study 28196207 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib as sole therapy
Number of subjects: 695
Study 28196207 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional systemic agents
Number of subjects: 695
Study 28196207 — intervention group
Group type: EXPERIMENTAL
Intervention: Resequencing studies
Number of subjects: 695
Study 26281285 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives of Euro 150
Number of subjects: 700
Study 26281285 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives of Euro 300
Number of subjects: 700
Study 26281285 — intervention group
Group type: COMPARATOR
Intervention: No financial incentive
Number of subjects: 700
Study 23340492 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (daily supplementation with 1200 mg n-3 LCPUFAs and dietary counseling to reduce arachidonic acid (AA) intake)
Number of subjects: 208
Study 23340492 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 208
Study 23340492 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet (Control)
Number of subjects: 208
Study 20666677 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylated atelocollagen
Number of subjects: 6
Study 20666677 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative fractional resurfacing laser
Number of subjects: 6
Study 20666677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 19388569 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and prolonged peritoneal lavage
Number of subjects: 35
Study 19388569 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 35
Study 17971621 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct attention training for reading impairment in mild aphasia
Number of subjects: 1
Study 15245938 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent gemcitabine (initial dose 10 mg/m2, increased as tolerated) and radiotherapy (RT)
Number of subjects: 24
Study 15245938 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of gemcitabine (greater than 20 mg/m2)
Number of subjects: 24
Study 15245938 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who experienced dose-limiting toxicity (DLT)
Number of subjects: 24
Study 11403535 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs) for long-term management of H. pylori-negative ulcers
Number of subjects: 0
Study 11403535 — intervention group
Group type: COMPARATOR
Intervention: H2-receptor antagonists
Number of subjects: 0
Study 9678430 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron gluconate
Number of subjects: 39
Study 9678430 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ferrous iron
Number of subjects: 39
Study 9678430 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iron supplementation)
Number of subjects: 39
Study 8048390 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 64
Study 8048390 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) plus Radiotherapy (RT)
Number of subjects: 64
Study 2659312 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy food supplement of 3.31 MJ for the first 3 months of the 6-month intervention period.
Number of subjects: 0
Study 2659312 — intervention group
Group type: COMPARATOR
Intervention: Standard health care similar to that offered by the local health service (unsupplemented group).
Number of subjects: 0
Study 31809657 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NTG)
Number of subjects: 32
Study 31809657 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 32
Study 31444897 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 222
Study 27900778 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) and stabilization
Number of subjects: 72
Study 25423953 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent (BES)
Number of subjects: 573
Study 25423953 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent (BES) in STEMI patients
Number of subjects: 573
Study 23260801 — intervention group
Group type: EXPERIMENTAL
Intervention: Banded LRYGB
Number of subjects: 60
Study 23260801 — intervention group
Group type: COMPARATOR
Intervention: Unbanded LRYGB
Number of subjects: 60
Study 21437746 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal tube
Number of subjects: 398
Study 21437746 — intervention group
Group type: COMPARATOR
Intervention: No transanal tube
Number of subjects: 398
Study 21437746 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal tube (double-staple technique subgroup)
Number of subjects: 398
Study 21437746 — intervention group
Group type: COMPARATOR
Intervention: No transanal tube (double-staple technique subgroup)
Number of subjects: 398
Study 18201641 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Internet Treatment (BIT)
Number of subjects: 446
Study 18201641 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 446
Study 16387937 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory pressure support of 10 cmH2O
Number of subjects: 29
Study 16387937 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory pressure support of 5 cmH2O (Control)
Number of subjects: 29
Study 12590028 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey at 2 weeks after death
Number of subjects: 207
Study 12590028 — intervention group
Group type: COMPARATOR
Intervention: Survey at 6 weeks after death
Number of subjects: 207
Study 11199864 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ISDN
Number of subjects: 38
Study 11199864 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ISDN
Number of subjects: 38
Study 11199864 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg SR ISDN
Number of subjects: 38
Study 11199864 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg SR ISDN
Number of subjects: 38
Study 11199864 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg SR ISDN (3x dosing)
Number of subjects: 38
Study 11199864 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 38
Study 8776643 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP 7.5 pMol/kg/min
Number of subjects: 30
Study 8776643 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone (C)
Number of subjects: 30
Study 1362228 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 2
Study 6749207 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen level
Number of subjects: 792
Study 6749207 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure
Number of subjects: 792
Study 6749207 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cholesterol
Number of subjects: 792
Study 6749207 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 792
Study 30854986 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.7 g/d of DHA
Number of subjects: 154
Study 30854986 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.7 g/d of EPA
Number of subjects: 154
Study 30854986 — intervention group
Group type: COMPARATOR
Intervention: 3 g/d of maize oil
Number of subjects: 154
Study 29481661 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab
Number of subjects: 216
Study 29481661 — intervention group
Group type: COMPARATOR
Intervention: infliximab (IMPACT 2)
Number of subjects: 216
Study 27593504 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (100 μg) and vilanterol (25 μg) once daily
Number of subjects: 2799
Study 27593504 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2799
Study 24573180 — intervention group
Group type: COMPARATOR
Intervention: Hyperoxic PECO (FiO2 = 1.0)
Number of subjects: 14
Study 24573180 — intervention group
Group type: COMPARATOR
Intervention: Hypoxic PECO (target SPo2 = 85%)
Number of subjects: 14
Study 24573180 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxic PECO (room air)
Number of subjects: 14
Study 22231020 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentrate (450 g/day)
Number of subjects: 36
Study 22231020 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate concentrate (300 g/day)
Number of subjects: 36
Study 22231020 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concentrate (150 g/day)
Number of subjects: 36
Study 22231020 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossbred goats
Number of subjects: 36
Study 22231020 — intervention group
Group type: EXPERIMENTAL
Intervention: Local goats
Number of subjects: 36
Study 20102936 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day for 48 hours before and 48 hours after contrast medium administration
Number of subjects: 304
Study 20102936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 18854539 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose B vitamin supplementation (5 mg/d of folate, 25 mg/d of vitamin B(6), 1 mg/d of vitamin B(12))
Number of subjects: 409
Study 18854539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 18854539 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose B vitamin supplementation
Number of subjects: 409
Study 15892275 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SMI) plus conventional western medicine
Number of subjects: 56
Study 15892275 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medicine (Control)
Number of subjects: 56
Study 12038847 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-tricalcium phosphate (beta-TCP) bone void filler as an additive to autogenous bone graft material
Number of subjects: 0
Study 12038847 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone graft material
Number of subjects: 0
Study 10404806 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy, initial dose of 1-3 IU/m2 x day (9-27 microg/kg), tapered to 1.30+/−0.38 IU/m2 x day (11 g/kg)
Number of subjects: 38
Study 10404806 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 38
Study 7570327 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial regimens with surgical or percutaneous drainage
Number of subjects: 330
Study 7570327 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without enterococcus)
Number of subjects: 330
Study 7570327 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment regimens
Number of subjects: 330
Study 2202385 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with levodopa/carbidopa (Sinemet Plus)
Number of subjects: 14
Study 2202385 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 14
Study 2202385 — intervention group
Group type: COMPARATOR
Intervention: Active treatment and placebo
Number of subjects: 14
Study 7196705 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 100 mg IV
Number of subjects: 0
Study 7196705 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine with naloxone
Number of subjects: 0
Study 7196705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7196705 — intervention group
Group type: COMPARATOR
Intervention: Naloxone alone
Number of subjects: 0
Study 31860597 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated patient teaching session (n=73)
Number of subjects: 144
Study 31860597 — intervention group
Group type: COMPARATOR
Intervention: Standard clinician-supervised learning in the operating theatre (n=71)
Number of subjects: 144
Study 31213078 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional hospital preoperative total knee arthroplasty education program with an additional 30‐minute group pain neuroscience education session
Number of subjects: 120
Study 31213078 — intervention group
Group type: COMPARATOR
Intervention: Traditional hospital preoperative total knee arthroplasty education program
Number of subjects: 120
Study 26992420 — intervention group
Group type: EXPERIMENTAL
Intervention: FD-OCT
Number of subjects: 13418
Study 26992420 — intervention group
Group type: COMPARATOR
Intervention: IVUS
Number of subjects: 13418
Study 26193218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 33
Study 26193218 — intervention group
Group type: COMPARATOR
Intervention: Histopathology
Number of subjects: 33
Study 22456951 — intervention group
Group type: EXPERIMENTAL
Intervention: DEN (200 mg/kg body weight) followed by 2-acetylamino fluorine (150 mg/kg body weight)
Number of subjects: 0
Study 22456951 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 21342217 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/RTV) 300/100 mg every 24 h for 14 days
Number of subjects: 24
Study 21342217 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV) 400 mg every 24 h for 14 days
Number of subjects: 24
Study 19522655 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 followed 2 months later by PPV23
Number of subjects: 0
Study 19522655 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 followed 6 months later by PPV23
Number of subjects: 0
Study 19522655 — intervention group
Group type: COMPARATOR
Intervention: PPV23
Number of subjects: 0
Study 16865614 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy (PEG)
Number of subjects: 70
Study 16865614 — intervention group
Group type: COMPARATOR
Intervention: Surgical gastrostomy (SG)
Number of subjects: 70
Study 12629374 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate
Number of subjects: 141
Study 12629374 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact laser prostatectomy
Number of subjects: 141
Study 12629374 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrovaporization
Number of subjects: 141
Study 12629374 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 141
Study 11113837 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback therapy (BF) alone
Number of subjects: 48
Study 11113837 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy (BF) + oral laxatives (LAX)
Number of subjects: 48
Study 9288198 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear vestibulo-ocular reflexes (LVOR) measured during lateral whole-body translation
Number of subjects: 14
Study 9288198 — intervention group
Group type: COMPARATOR
Intervention: Normal cases (control group)
Number of subjects: 14
Study 9288198 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mild LVOR asymmetries
Number of subjects: 14
Study 8421417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (once-a-day)
Number of subjects: 114
Study 8421417 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (three times a day)
Number of subjects: 114
Study 3524724 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 24
Study 3524724 — intervention group
Group type: COMPARATOR
Intervention: Gluten-containing diet (control)
Number of subjects: 24
Study 29480198 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-hour multisensory virtual simulation experience
Number of subjects: 278
Study 29480198 — intervention group
Group type: COMPARATOR
Intervention: Standard curriculum only
Number of subjects: 278
Study 26871692 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation group (18-32 min pulsed current, stimulation frequency 80 Hz, pulse duration 400 μs, stimulation intensity 40% of maximal isometric voluntary contraction)
Number of subjects: 45
Study 26871692 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (electrical stimulation plus laser therapy)
Number of subjects: 45
Study 26871692 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser group (dose 4-6 J per point, 6 points at the knee joint)
Number of subjects: 45
Study 26871692 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control period)
Number of subjects: 45
Study 24755192 — intervention group
Group type: EXPERIMENTAL
Intervention: m-TOR therapy (SRL and EVL)
Number of subjects: 30
Study 24755192 — intervention group
Group type: EXPERIMENTAL
Intervention: m-TOR therapy
Number of subjects: 30
Study 23203669 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of physicians per 10,000 persons in Europe
Number of subjects: 0
Study 23203669 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of physicians per 10,000 persons in Asia
Number of subjects: 0
Study 23203669 — intervention group
Group type: EXPERIMENTAL
Intervention: Region as a function of the number of physicians
Number of subjects: 0
Study 21302489 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaogen Decoction (SGD) administered 10 mL, thrice a day, increased to every 2 hours if 2nd or over 2nd grade ARE occurred.
Number of subjects: 60
Study 21302489 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with antibiotics (cefuroxime 4.5 g) and hormone (dexamethasone 5 mg) by intravenous infusion for 7 days.
Number of subjects: 60
Study 21302489 — intervention group
Group type: EXPERIMENTAL
Intervention: SGD group
Number of subjects: 60
Study 21302489 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 18394624 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene covers (Gladwrap)
Number of subjects: 116
Study 18394624 — intervention group
Group type: COMPARATOR
Intervention: Lanolin eye ointment (Duratears)
Number of subjects: 116
Study 16340472 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-delivered intervention
Number of subjects: 497
Study 16340472 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care control
Number of subjects: 497
Study 15536894 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes patients
Number of subjects: 26
Study 15536894 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 26
Study 11550964 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide 20 mg/day
Number of subjects: 0
Study 11550964 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine 2 g/day
Number of subjects: 0
Study 11550964 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched to sulfasalazine at Month 6)
Number of subjects: 0
Study 9663720 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg for 10 weeks
Number of subjects: 29
Study 9663720 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone 32 mg for 3 weeks with tapering
Number of subjects: 29
Study 7819986 — intervention group
Group type: EXPERIMENTAL
Intervention: Whisky
Number of subjects: 4
Study 7819986 — intervention group
Group type: EXPERIMENTAL
Intervention: Brandy
Number of subjects: 4
Study 7819986 — intervention group
Group type: EXPERIMENTAL
Intervention: Whisky and Brandy
Number of subjects: 4
Study 3065267 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral minocycline
Number of subjects: 96
Study 3065267 — intervention group
Group type: COMPARATOR
Intervention: Topical tetracycline ointment
Number of subjects: 96
Study 3065267 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 96
Study 30595284 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus-eluting coronary stents
Number of subjects: 204
Study 30595284 — intervention group
Group type: COMPARATOR
Intervention: Biodegradable polymer-based sirolimus-eluting coronary stents
Number of subjects: 204
Study 28512843 — intervention group
Group type: EXPERIMENTAL
Intervention: New brightening complex cream containing niacinamide, tranexamic acid, oxyresveratrol, glutathione disulfide, and linoleic acid applied on the face two times per day for 12 weeks
Number of subjects: 26
Study 28512843 — intervention group
Group type: EXPERIMENTAL
Intervention: New brightening complex cream
Number of subjects: 26
Study 26387055 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (400 mcg)
Number of subjects: 101
Study 26387055 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial nitroglycerin (200 mcg)
Number of subjects: 101
Study 26387055 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (400 mcg) in patients < 1.65 m height
Number of subjects: 101
Study 26387055 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (400 mcg) in patients with diabetes
Number of subjects: 101
Study 26387055 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (400 mcg) in smokers
Number of subjects: 101
Study 23107873 — intervention group
Group type: EXPERIMENTAL
Intervention: S18886 30 mg/d for 5 days
Number of subjects: 20
Study 23107873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21959813 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (2 or 4 mg)
Number of subjects: 50
Study 21959813 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine (25 or 50 mg)
Number of subjects: 50
Study 21959813 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (50 μg)
Number of subjects: 50
Study 21959813 — intervention group
Group type: EXPERIMENTAL
Intervention: All opioids (morphine, pethidine, fentanyl)
Number of subjects: 50
Study 21959813 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 50
Study 18294482 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin 120 IU/kg s.c. (maximum 10,000 IU) twice daily for 5 to 7 days in hospital, followed by placebo for 3 months (n = 285)
Number of subjects: 555
Study 18294482 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex- and weight-adjusted doses of dalteparin (5000 or 7500 IU) twice daily for 3 months (n = 270)
Number of subjects: 555
Study 18294482 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin treatment
Number of subjects: 555
Study 18294482 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 555
Study 16169705 — intervention group
Group type: COMPARATOR
Intervention: Modified Reliable Change Index (RCI) methodology applied across a battery of neuropsychological tests
Number of subjects: 57